# US 2024/0200059 A1 · Photocleavable guide rnas and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200059 A1
- Document ID: US20240200059A1
- Status: Published application
- Kind: A1
- Application number: 18/285,765
- Filed: 2022-04-08
- Published: 2024-06-20
- Earliest claimed: 2021-04-09
- Assignees: Vor Biopharma Inc.
- Applicants: Vor Biopharma Inc.
- Inventors: Dane Hazelbaker; Elizabeth Paik
- Web page: https://patentgrep.com/patent/US20240200059A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/3183: Diol linkers, e.g. glycols or propanediols
- C12N 2310/3511: intercalating or cleaving agent
- C12N 2320/53: reducing unwanted side-effects
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are photocleavable guide RNAs (gRNAs) comprising a targeting domain, a CRISPR RNA (crRNA) sequence for a CRISPR/Cas nuclease, and a at least one photocleavable moiety. Also provided herein are methods involving contacting a photocleavable gRNA and a CRISPR/Cas nuclease to form a CRISPR system. Also provided herein are methods involving providing a cell and contacting the photocleavable gRNA and a CRISPR/Cas nuclease, thus forming a ribonucleoprotein complex that binds to a target site sequence in the genome of the cell.

## Claims

### Claim 1

A guide RNA (gRNA) comprising:
a targeting domain;
a CRISPR RNA (crRNA) sequence for a CRISPR/Cas nuclease; and
at least one photocleavable moiety.

### Claim 2 (depends on 1)

The gRNA of claim 1, wherein the gRNA comprises 1, 2, 3, 4, 5, or more photocleavable moieties.

### Claim 3 (depends on 1, 2)

The gRNA of claim 1 or 2, wherein the photocleavable moiety is a 2-nitrobenzyl bond.

### Claim 4 (depends on 1, 2, 3)

The gRNA of any one of claims 1-3, wherein the targeting domain is corresponding to a target site sequence adjacent to a protospacer-adjacent motif (PAM) in a gene.

### Claim 5 (depends on 1, 2, 3, 4)

The gRNA of any one of claims 1-4, wherein the crRNA sequence comprises a first complementarity domain, a linking domain, and a second complementarity domain that is complementary to the first complementarity domain; and a proximal domain.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The gRNA of any one of claims 1-5, wherein the at least one photocleavable moiety is located within the targeting domain, wherein the photocleavable moiety is located between two nucleotides of the targeting domain at a position corresponding to a nucleotide of the target site sequence.

### Claim 7 (depends on 6)

The gRNA of claim 6, wherein the at least one photocleavable moiety is located following nucleotide position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 from the 5′ end of the targeting domain.

### Claim 8 (depends on 6, 7)

The gRNA of claim 6 or 7, wherein the at least one photocleavable moiety is located following nucleotide position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 from the 5′ end of the gRNA.

### Claim 9 (depends on 6, 7, 8)

The gRNA of any one of claims 6-8, wherein the at least one photocleavable moiety is located at any one or more of positions 9, 11, 13, 15, or 17 from the 5′ end of the targeting domain.

### Claim 10 (depends on 6, 7, 8, 9)

The gRNA of any one of claims 6-9, wherein the at least one photocleavable moiety is located at any one or more of positions 9, 11, 13, 15, or 17 from the 5′ end of the gRNA.

### Claim 11 (depends on 6, 7, 8, 9, 10)

The gRNA of any one of claims 6-10, wherein the at least one photocleavable moiety is located between nucleotide positions 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, 19 and 21, or 20 and 22 from the 5′ end of the targeting domain.

### Claim 12 (depends on 6, 7, 8, 9, 10, 11)

The gRNA of any one of claims 6-11, wherein the at least one photocleavable moiety is located between nucleotide positions 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, 19 and 21, or 20 and 22 from the 5′ end of the gRNA.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

The gRNA of any one of claims 6-12, wherein the at least one photocleavable moiety is located within 5, 10, or 15 nucleotides from the 3′ end of the targeting domain.

### Claim 14 (depends on 6, 7, 8, 9, 10, 11, 12, 13)

The gRNA of any one of claims 6-13, wherein the at least one photocleavable moiety is located within the targeting domain following a position corresponding to the nucleotide at a position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 nucleotides adjacent to the PAM.

### Claim 15 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14)

The gRNA of any one of claims 6-14, wherein the at least one photocleavable moiety is located within the targeting domain between nucleotide positions 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, 19 and 21, 20 and 22, or 21 and 23 adjacent to the PAM.

### Claim 16 (depends on 14)

The gRNA of claim 14, wherein the at least one photocleavable moiety is located within the targeting domain following a position corresponding to the nucleotide at one or more of positions 9, 11, 13, 15, or 17 nucleotides adjacent to the PAM.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The gRNA of any one of claims 1-16, wherein the at least one photocleavable moiety is located within the crRNA sequence, wherein the photocleavable moiety is located between two nucleotides of the cRNA sequence replacing a nucleotide of a corresponding wildtype crRNA sequence.

### Claim 18 (depends on 17)

The gRNA of claim 17, wherein the at least one photocleavable moiety is located following nucleotide position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 from the 5′ end of the crRNA sequence.

### Claim 19 (depends on 17)

The gRNA of claim 17, wherein the at least one photocleavable moiety is located following nucleotide position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 from the 5′ end of the gRNA.

### Claim 20 (depends on 17, 18, 19)

The gRNA of any one of claims 17-19, wherein the at least one photocleavable moiety is located within 5, 10, or 15 nucleotides from the 3′ end of the crRNA sequence.

### Claim 21 (depends on 17, 18, 19, 20)

The gRNA of any one of claims 17-20, wherein the at least one photocleavable moiety is located within 5, 10, or 15 nucleotides from the 3′ end of the gRNA.

### Claim 22 (depends on 17, 18, 19, 20, 21)

The gRNA of any one of claims 17-21, wherein the at least one photocleavable moiety is located between nucleotide positions 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, 19 and 21 from the 5′ end of the crRNA sequence.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The gRNA of any one of claims 17-22, wherein the at least one photocleavable moiety is located between nucleotide positions 1 and 3, 2 and 4, 3 and 5, 4 and 6, 5 and 7, 6 and 8, 7 and 9, 8 and 10, 9 and 11, 10 and 12, 11 and 13, 12 and 14, 13 and 15, 14 and 16, 15 and 17, 16 and 18, 17 and 19, 18 and 20, or 19 and 21 from the 5′ end of the gRNA.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The gRNA of any one of claims 1-23, wherein the CRISPR/Cas nuclease is a Cas12a (Cpf1) nuclease.

### Claim 25 (depends on 24)

The gRNA of claim 24, wherein the Cas12a nuclease is AsCas12a, LbCas12a, FnCas12a, or PaCas 12a nuclease.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The gRNA of any one of claims 1-23, wherein the CRISPR/Cas nuclease is a Cas9 nuclease.

### Claim 27 (depends on 26)

The gRNA of claim 26, wherein the gRNA is a single guide RNA (sgRNA).

### Claim 28 (depends on 27)

The gRNA of claim 27, wherein at least one photocleavable moiety is located within 10, 15, or 20 nucleotides of the 5′ end of the sgRNA.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The gRNA of any of claims 1-28, wherein the gRNA comprises one or more nucleotide residues that are chemically modified.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The gRNA of any of claims 1-29, wherein the gRNA comprises one or more nucleotide residues that comprise a 2′O-methyl moiety.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The gRNA of any of claims 1-30, wherein the gRNA comprises one or more nucleotide residues that comprise a phosphorothioate.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The gRNA of any of claims 1-31, wherein the gRNA comprises one or more nucleotide residues that comprise a thioPACE moiety.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The gRNA of any one of claims 1-32, wherein the gRNA is capable of directing the CRISPR nuclease to a target site sequence.

### Claim 34

The gRNA of any one of the preceding claims, wherein the gRNA comprises a sequence of any one of SEQ ID NOs: 1-40.

### Claim 35

The gRNA of any one of the preceding claims, wherein the wherein the gRNA comprises a sequence of any one of SEQ ID NO: 41-43.

### Claim 36

The gRNA of any one of the preceding claims, wherein the gRNA comprises a sequence of any one of SEQ ID NOs: 134-172, 174, 176, 178, and 180.

### Claim 37

The gRNA of any one of the preceding claims, wherein the wherein the gRNA comprises a sequence of any one of SEQ ID NOs: 181-190.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A CRISPR system comprising a CRISPR/Cas nuclease and the gRNA of any one of claims 1-37.

### Claim 39 (depends on 38)

The CRISPR system of claim 38, wherein the CRISPR/Cas nuclease is a Cas12a (Cpf1) nuclease.

### Claim 40 (depends on 39)

The CRISPR system of claim 39, wherein the Cas 12a nuclease is AsCas12a, LbCas12a, FnCas12a, or PaCas12a nuclease.

### Claim 41 (depends on 38)

The CRISPR system of claim 38, wherein the CRISPR/Cas nuclease is a Cas9 nuclease.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method, comprising contacting the gRNA of any one of claims 1-37 and a CRISPR/Cas nuclease to form a CRISPR system.

### Claim 43 (depends on 42)

The method of claim 42, wherein the CRISPR/Cas nuclease is a Cas12a (Cpf1) nuclease.

### Claim 44 (depends on 43)

The method of claim 43, wherein the Cas12a nuclease is AsCas12a, LbCas 12a, FnCas12a, or PaCas12a nuclease.

### Claim 45 (depends on 42)

The method of claim 42, wherein the CRISPR/Cas nuclease is a Cas9 nuclease.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method, comprising
a. providing a cell, and
b. contacting a cell with (i) the gRNA of any one of claims 1-37 and (ii) a CRISPR/Cas nuclease, thus forming a ribonucleoprotein (RNP) complex under conditions suitable for the gRNA of (i) to form and/or maintain an RNP complex with the CRISPR/Cas nuclease of (ii), thus forming a CRISPR system, and for the RNP complex to bind a target site sequence in the genome of the cell.

### Claim 47 (depends on 46)

The method of claim 46, wherein the contacting comprises introducing (i) and (ii) into the cell in the form of a pre-formed ribonucleoprotein (RNP) complex.

### Claim 48 (depends on 46)

The method of claim 46, wherein the contacting comprises introducing (i) and/or (ii) into the cell in the form of a nucleic acid encoding the gRNA of (i) and/or the CRISPR/Cas nuclease of (ii).

### Claim 49 (depends on 48)

The method of claim 48, wherein the nucleic acid encoding the gRNA of (i) and/or the CRISPR nuclease of (ii) is an RNA, preferably an mRNA or an mRNA analog.

### Claim 50 (depends on 47)

The method of claim 47, wherein the pre-formed RNP complex is introduced into the cell via electroporation.

### Claim 51 (depends on 46, 47, 48, 49, 50)

The method of any one of claims 46-50, wherein the method further comprises contacting the cell with light such that at least 50% of the photocleavable moiety is cleaved.

### Claim 52 (depends on 46, 47, 48, 49, 50, 51)

The method of any one of claims 46-51, wherein the method further comprises contacting the cell with light resulting in at least a 50% reduction of cleavage by the CRISPR/Cas nuclease at the target site sequence.

### Claim 53 (depends on 51, 52)

The method of claim 51 or 52, wherein the light has a wavelength of about 350-375 nm.

### Claim 54 (depends on 53)

The method of claim 53, wherein the light has a wavelength of about 365 nm.

### Claim 55 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 46-54, wherein the cell is contacted with light for between 10 seconds and 60 seconds.

### Claim 56 (depends on 55)

The method of claim 55, wherein the cell is contacted with light for about 30 seconds.

### Claim 57 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 46-56, wherein the cell is a hematopoietic cell.

### Claim 58 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 46-57, wherein the cell is a hematopoietic stem cell.

### Claim 59 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 46-58, wherein the cell is a hematopoietic progenitor cell.

### Claim 60 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 46-56, wherein the cell is an immune effector cell.

### Claim 61 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 60)

The method of any one of claim 46-56 or 60, wherein the cell is a lymphocyte.

### Claim 62 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 60)

The method of any one of claim 46-56, 60, or 61, wherein the cell is a T-lymphocyte.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

A genetically engineered cell, wherein the cell is obtained by the method of any of claims 46-62.

### Claim 64 (depends on 63)

A cell population, comprising the genetically engineered cell of claim 63.
